With the aid of the standardized WOMAC* questionnaire (for the evaluation of pain, mobility and physical state of the patient), clinical studies have shown that patients with osteoarthritis of the knee can make an improvement in all three criteria with Orthokine® therapy.
The efficacy of Orthokine® serum was examined in a prospective, controlled comparative trial comprising 376 patients with knee osteoarthritis, comparing it to placebo and hyaluronic acid. Pain relief under Orthokine® therapy was above 50 % and thus numerically higher on the Womac pain score in indirect comparison of the available studies with other intra-articular treatments such as steroids, hyaluronic acid or PRGF1, 2, 3, 4.
No direct comparative study demonstrating significantly superior pain reduction is available yet.
Two years after the Orthokine® therapy, patients with knee osteoarthritis showed significantly better results in terms of pain, mobility and physical status (Womac score) compared to the other treatment arms (placebo and hyaluronic acid).
Degenerative changes to the spine, especially lumbar spinal stenosis, facet syndrome, and radiculitis, are common conditions which can, in some cases, cause significant limitations to a patient’s quality of life. Clinical studies have shown that local Orthokine® therapy provides a good alternative to local steroid therapies for the treatment of back pain.
In a controlled, prospective clinical study, compared against two different dosages of local steroid therapy with triamcinolone (5 mg or 10 mg), local Orthokine® therapy shows:
In a retrospective clinical study in 261 patients with degenerative dorsal pain, under treatment with Orthokine® serum on average a reduction in pain intensity from 70 % to 33 % (VAS – Visual Analogue Scale) was observed. (Confirmatory evidence from a prospective, blinded clinical trial is still pending.)